2020 - Axcelead

Japanese Website

Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline

Inhibition of PKCtheta as a therapeutic target …

Michael Jaramillo2023-12-18T21:05:08+00:0012.10.2020|

Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi)

Current Pharmaceutical Biotechnology

Michael Jaramillo2023-12-01T16:40:50+00:0011.09.2020|

Bidirectional, non-necrotizing glomerular crescents are the critical pathology in X-linked Alport syndrome mouse model harboring nonsense mutation of human COL4A5

Scientific Reports

Michael Jaramillo2023-12-01T16:40:08+00:0011.03.2020|

Axcelead and Kyowa Kirin Started an Innovative Collaboration in Small-Molecule Drug Development

Tokyo, Japan, October 2, 2020 —Axcelead Drug Discovery …

Michael Jaramillo2023-11-29T22:59:16+00:0010.02.2020|

Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment

Journal of Pharmacological and Toxicological Methods

Michael Jaramillo2023-12-01T16:41:42+00:0006.18.2020|

Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications

June 29,2020- Otsuka Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, …

Michael Jaramillo2023-11-29T23:02:57+00:0006.17.2020|

Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis

PLOS ONE

Michael Jaramillo2023-12-01T16:42:24+00:0001.28.2020|